CpG 7909, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Treatment

This study is ongoing, but not recruiting participants.
Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:

1		Conditions listed in this trial
			Lymphoma
2		Additional conditions recognized in this trial
			Lymphoma, Non-Hodgkin
3		More general conditions related to this trial
			Immune System Diseases
			Immunoproliferative Disorders
			Lymphatic Diseases
			Lymphoproliferative Disorders
			Neoplasms
			Neoplasms by Histologic Type
4		Interventions listed in this trial
			CpG 7909
			indium In 111 ibritumomab tiuxetan
			rituximab
			yttrium Y 90 ibritumomab tiuxetan
			flow cytometry
			immunologic technique
			laboratory biomarker analysis
			radionuclide imaging
5		Additional drug interventions recognized in this trial
			Antibodies, Monoclonal
6		More general drug interventions related to this trial
			Antineoplastic Agents
			Antirheumatic Agents
			Immunologic Factors
			Pharmacologic Actions
			Physiological Effects of Drugs
			Therapeutic Uses
7		Sponsors listed in this trial
			Mayo Clinic
			National Cancer Institute (NCI)